Back to Infectious Disease
Infectious Diseasev2013Evidence-Based

Drug Resistance in Pneumonia (DRIP) Score

Predicts risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Helps determine when broad-spectrum antibiotics should be used to ensure effective treatment while avoiding unnecessary antibiotic resistance.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
drip score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Drug Resistance in Pneumonia (DRIP) Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within infectious disease.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Major risk factors (2 points each): Antibiotic use within 60 days, Long-term care facility residence, Tube feeding, Prior drug-resistant infection. Minor risk factors (1 point each): Chronic pulmonary disease, Hospitalization within 60 days, Poor functional status, MRSA colonization, Wound care, Gastric acid suppression. Total: 0-14 points.

Clinical Pearls & Practice Notes

  • The DRIP score should only be used for bacterial causes of pneumonia.
  • At threshold ≥4 points: Sensitivity 0.82, Specificity 0.81, PPV 0.68, NPV 0.90.
  • DRIP score is more predictive than healthcare-associated pneumonia (HCAP) criteria for drug-resistant pathogens.
  • May decrease antibiotic overutilization by 46% compared to HCAP criteria.
  • False negatives may occur with MRSA, P. aeruginosa, severe COPD, IV drug use, psychiatric illness, and homelessness.
  • False positives may occur with S. pneumoniae and methicillin-susceptible S. aureus (MSSA).
  • Local validation and institutional antibiotic resistance patterns should be considered for optimal implementation.

Evidence & Literature Citations

  1. Webb BJ, Dascomb K, Stenehjem E, Dean N. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother. 2016;60(5):2652-63. doi: 10.1128/AAC.03071-15.
  2. Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J. 2011;38(4):878-87. doi: 10.1183/09031936.00141110.
  3. Webb BJ, Dangerfield B, Pasha JS, et al. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med. 2012;106(11):1606-12. doi: 10.1016/j.rmed.2012.08.010.

Score Interpretation Ranges

Low Risk0 – 3 pts

Low risk of drug-resistant pneumonia

High Risk4 – 14 pts

High risk of drug-resistant pneumonia

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.